Clinical Trials
36 trialsAdoptive Transfer of Tumor Infiltrating Lymphocytes for Advanced Solid Cancers
University of Pittsburgh
Multicenter Trial of ESK981 in Patients With Select Solid Tumors
University of Michigan Rogel Cancer Center
DOTATOC PET/CT for Imaging NET Patients
British Columbia Cancer Agency
PLANE-PC
University of Michigan Rogel Cancer Center
Lutathera in People With Gastroenteropancreatic (GEP), Bronchial or Unknown Primary Neuroendocrine Tumors That Have Spread to the Liver
Memorial Sloan Kettering Cancer Center
Lumed
University Hospital, Basel, Switzerland
Analysis of Optimal Treatment Sequencing of Surufatinib and Somatostatin Analogs in Neuroendocrine Tumors: A Retrospective Cohort Study
West China Hospital
Study of Cabozantinib With Lu-177 in Patients With Somatostatin Receptor 2 Positive Neuroendocrine Tumors
Providence Health & Services
I-MAT
Melanoma and Skin Cancer Trials Limited
GoTHAM
Melanoma and Skin Cancer Trials Limited
Dual Tracer (68Ga-DOTATATE and 18F-FDG) PET Imaging in G2 & G3 Gastroenteropancreatic Neuroendocrine Tumors
University Health Network, Toronto
Lenvatinib and Everolimus in Treating Patients With Advanced, Unresectable Carcinoid Tumors
M.D. Anderson Cancer Center
Telotristat Ethyl for the Treatment of Carcinoid Heart Disease in Patients With Metastatic Neuroendocrine Tumor
M.D. Anderson Cancer Center
Defining Response Criteria for PET Scans for People With Neuroendocrine Tumors
Memorial Sloan Kettering Cancer Center
MOST-CIRCUIT
Olivia Newton-John Cancer Research Institute
FAPI PET RDRC
Jonsson Comprehensive Cancer Center
Abemaciclib in Treating Patients With Advanced, Refractory, and Unresectable Digestive System Neuroendocrine Tumors
University of Washington
PELICAN
Imperial College London
Nivolumab and Temozolomide in Treating Patients With Recurrent or Refractory Small-Cell Lung Cancer or Advanced Neuroendocrine Cancer
Ohio State University Comprehensive Cancer Center
NET-PRO
University of Iowa
Lu-DOTATATE Treatment in Patients With 68Ga-DOTATATE Somatostatin Receptor Positive Neuroendocrine Tumors
University Health Network, Toronto
Lesion-to-lesion Comparison of 68Ga-HA-DOTATATE, 18F-DOPA, and 18F-FDG PET/CT in the Evaluation of Metastatic Neuroendocrine Tumors
University of Alberta
A Safety Study of 212Pb-VMT-alpha-NET in Patients With Neuroendocrine Tumors
University of Iowa
Pembrolizumab With Liver-Directed or Peptide Receptor Radionuclide Therapy for Neuroendocrine Tumors and Liver Metastases
University of California, San Francisco
NP-101 (TQ Formula) With Nivolumab and Ipilimumab in Advanced or Metastatic Extra-pulmonary Neuroendocrine Carcinomas
Case Comprehensive Cancer Center
Gallium 68 Pentixafor in Patients With Neuroendocrine Tumors
University of Iowa
A First-in-human Clinical Trial to Evaluate an Alpha-radiation Imaging Agent
University of Iowa
Trinav
Abramson Cancer Center at Penn Medicine
Multicenter Retrospective Database on Prognostic and Predictive Factors in Patients With Neuroendocrine Tumors
Latin American Cooperative Oncology Group
RADNET
Uppsala University
VISIONARY
Peking University
LUTHREE
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
P-PRRT
CHU de Quebec-Universite Laval
CABONEN
University Medical Center Goettingen
Nonfunctioning Small (≤2 cm) Neuroendocrine Pancreatic Incidentaloma
Société Française d'Endoscopie Digestive
Study to Evaluate the Safety of Combining Two Radionuclide Therapies to Treat Mid-gut Neuroendocrine Tumors
University of Iowa